do-me/EUR-LEX huggingface dataset:
Case T-275/24: Judgment of the General Court of 10 December 2025 – V4 Holding v EUIPO – V4 Financial Partners (V4 Financial Partners) (EU trade mark – Invalidity proceedings – EU figurative mark V4 Financial Partners – Earlier national figurative mark V4 – Relative ground for invalidity – Likelihood of confusion – Article 8(1)(b) and Article 60(1)(a) of Regulation (EU) 2017/1001)
Date: 2025-12-10
Institutions: General Court
Subjects: EU trade mark, business management, consultancy, economic analysis, financial analysis, financial services, marketing, provision of services, registered trade mark, trade-mark law








C_202600474EN.000101.fmx.xml












Official Journal of the European Union


EN
C series













C/2026/474


2.2.2026






Judgment of the General Court of 10 December 2025 – V4 Holding v EUIPO – V4 Financial Partners (V4 Financial Partners)


(Case T-275/24)
                (1)

(EU trade mark - Invalidity proceedings - EU figurative mark V4 Financial Partners - Earlier national figurative mark V4 - Relative ground for invalidity - Likelihood of confusion - Article 8(1)(b) and Article 60(1)(a) of Regulation (EU) 2017/1001)
(C/2026/474)
Language of the case: English

Parties


Applicant: V4 Holding, a.s. (Čadca, Slovakia) (represented by: M. Michalec, lawyer)

Defendant: European Union Intellectual Property Office (represented by: R. Raponi, acting as Agent)

Other party to the proceedings before the Board of Appeal of EUIPO: V4 Financial Partners, SA (Madrid, Spain)

Re:

By its action under Article 263 TFEU, the applicant seeks the annulment of the decision of the Fourth Board of Appeal of the European Union Intellectual Property Office (EUIPO) of 15 March 2024 (Case R 2203/2022-4).

Operative part of the judgment

The Court:






1.


Annuls the decision of the Fourth Board of Appeal of the European Union Intellectual Property Office (EUIPO) of 15 March 2024 (Case R 2203/2022-4);











2.


Orders EUIPO to pay the costs.






(1)  
            OJ C, C/2024/4099, 8.7.2024.


ELI: http://data.europa.eu/eli/C/2026/474/oj
ISSN 1977-091X (electronic edition)
Case C-806/25 P: Appeal brought on 10 December 2025 by European Commission against the judgment of the General Court (Fourth Chamber, Extended Composition) delivered on 24 September 2025 in Case T-256/23, Mylan Ireland v Commission
Date: 2025-12-10
Institutions: Court of Justice
Subjects: disease of the nervous system, drug surveillance, market approval, medicinal product








C_202600460EN.000101.fmx.xml












Official Journal of the European Union


EN
C series













C/2026/460


2.2.2026






Appeal brought on 10 December 2025 by European Commission against the judgment of the General Court (Fourth Chamber, Extended Composition) delivered on 24 September 2025 in Case T-256/23, Mylan Ireland v Commission


(Case C-806/25 P)

(C/2026/460)
Language of the case: English

Parties


Appellant: European Commission (represented by: L. Haasbeek, E. Mathieu, A. Spina, Agents)

Other parties to the proceedings: Mylan Ireland Ltd, Biogen Netherlands BV

Form of order sought

The appellant claims that the Court should:






—


set aside the judgment under the appeal;










—


dismiss the action as unfounded; and










—


order the applicant at first instance to bear the costs.





Pleas in law and main arguments

In support of the appeal, the appellant relies on single ground of appeal.
Error in law in the interpretation of Article 266 TFEU, as well as in interpretation of Article 14(11) of Regulation (EC) 726/2004 (1), in concluding that the Commission could not adopt Commission Implementing Decision C(2023) 3067 (final) of 2 May 2023 amending the marketing authorisation granted by Decision C(2014) 601 (final) for the medicinal product ‘Tecfidera’, recognising an additional year of marketing protection.


(1)  Regulation (EC) No 726/2004 of the European Parliament and of the Council of 31 March 2004 laying down Community procedures for the authorisation and supervision of medicinal products for human and veterinary use and establishing a European Medicines Agency (OJ 2004, L 136, p. 1).


ELI: http://data.europa.eu/eli/C/2026/460/oj
ISSN 1977-091X (electronic edition)
Case C-813/25 P: Appeal brought on 10 December 2025 by the European Commission against the judgment of the General Court (Fourth Camber) delivered on 24 September 2025 in Case T-309/23 Aliud Pharma GmbH v European Commission
Date: 2025-12-10
Institutions: Court of Justice
Subjects: disease of the nervous system, drug surveillance, market approval, medicinal product








C_202600467EN.000101.fmx.xml












Official Journal of the European Union


EN
C series













C/2026/467


2.2.2026






Appeal brought on 10 December 2025 by the European Commission against the judgment of the General Court (Fourth Camber) delivered on 24 September 2025 in Case T-309/23 Aliud Pharma GmbH v European Commission



(Case C-813/25 P)

(C/2026/467)
Language of the case: German

Parties


Appellant: European Commission (represented by: F. Erlbacher, L. Haasbeek, E. Mathieu and A. Spina, acting as Agents)

Other parties to the proceedings: Aliud Pharma GmbH, Biogen Netherlands BV

Form of order sought

The appellant claims that the Court should:






—


set aside the judgment under appeal;










—


dismiss the action at first instance as inadmissible;










—


order Aliud Pharma GmbH to pay the costs.





Grounds of appeal and main arguments

The European Commission relies on a single ground of appeal, alleging an error of law in the interpretation of Article 266 TFEU and Article 14(11) of Regulation (EC) No 726/2004. (1) The General Court made that error of law by ruling that the Commission was not able to issue Commission Implementing Decision C(2023) 3067 final of 2 May 2023 amending the marketing authorisation granted by Decision C(2014) 601 final for the medicinal product ‘Tecfidera’, which recognised an additional year of marketing protection.


(1)  Regulation (EC) No 726/2004 of the European Parliament and of the Council of 31 March 2004 laying down Community procedures for the authorisation and supervision of medicinal products for human and veterinary use and establishing a European Medicines Agency (OJ 2004 L 136, p. 1).


ELI: http://data.europa.eu/eli/C/2026/467/oj
ISSN 1977-091X (electronic edition)
Case T-849/25: Action brought on 10 December 2025 – Excursus v EUIPO – Bigfinite (AIZOON)
Date: 2025-12-10
Institutions: General Court
Subjects: EU trade mark, business management, computer system, consultancy, database, electronic publishing, registered trade mark, software, telecommunications, trade-mark law








C_202600671EN.000101.fmx.xml












Official Journal of the European Union


EN
C series













C/2026/671


9.2.2026






Action brought on 10 December 2025 – Excursus v EUIPO – Bigfinite (AIZOON)


(Case T-849/25)

(C/2026/671)
Language in which the application was lodged: English

Parties


Applicant: Excursus Srl (Torino, Italy) (represented by: N. Bottero and M. Travostino, lawyers)

Defendant: European Union Intellectual Property Office

Other party to the proceedings before the Board of Appeal: Bigfinite Inc. (San Francisco, California, United States)

Details of the proceedings before EUIPO


Proprietor of the trade mark at issue: Applicant before the General Court

Trade mark at issue: International registration designating the European Union in respect of the mark AIZOON – International registration designating the European Union No 1 297 288
         

Procedure before EUIPO: Cancellation proceedings

Contested decision: Decision of the First Board of Appeal of EUIPO of 6 October 2025 in Case R 656/2025-1

Form of order sought

The applicant claims that the Court should:






—


annul the contested decision as well as the decision No. C51836 issued by EUIPO Cancellation Division on 4 March 2025, which revoked the EU fraction of the international registration No. 1 297 288 trade mark ‘AIZOON’ for all the claimed products and services and, consequently






i)


alter the contested decision as well as the decision No. C51836 issued by EUIPO Cancellation Division on 4 March 2025, and, therefore, confirm the validity of the European Union trademark fraction of the international registration No. 1 297 288 for the concerned services or, in the alternative, for any of the services as it may be determined by the General Court; and/or










ii)


order and/or refer to the EUIPO to take the necessary measures to comply with the judgment of the General Court;














—


charge all the costs to the Bigfinite Inc. and/or to the EUIPO.





Pleas in law







—


Infringement of Articles 18(1)(a) and 58 of Regulation (EU) 2017/1001 of the European Parliament and of the Council and Articles 19 and 10(3) of Commission Delegated Regulation (EU) 2018/625;










—


Infringement of Articles 18 and 58 of Regulation (EU) 2017/1001 of the European Parliament and of the Council and Articles 19 and 10(3) of Commission Delegated Regulation (EU) 2018/625.






ELI: http://data.europa.eu/eli/C/2026/671/oj
ISSN 1977-091X (electronic edition)
Case T-81/25: Judgment of the General Court of 10 December 2025 – LTV Leuchten & Lampen v EUIPO – XAL (Lamps) (EU design – Invalidity proceedings – Registered EU design representing a lamp – Prior designs – Ground for invalidity – No disclosure of the prior designs – Prior designs produced after the filing of the application for a declaration of invalidity – Procedural irregularities before the Cancellation Division – Refusal to grant the applicant’s requests for measures of inquiry and for an oral hearing – Misuse of powers)
Date: 2025-12-10
Institutions: General Court
Subjects: designs and models, lighting equipment








C_202600648EN.000101.fmx.xml












Official Journal of the European Union


EN
C series













C/2026/648


9.2.2026






Judgment of the General Court of 10 December 2025 – LTV Leuchten & Lampen v EUIPO – XAL (Lamps)


(Case T-81/25)
                (1)

(EU design - Invalidity proceedings - Registered EU design representing a lamp - Prior designs - Ground for invalidity - No disclosure of the prior designs - Prior designs produced after the filing of the application for a declaration of invalidity - Procedural irregularities before the Cancellation Division - Refusal to grant the applicant’s requests for measures of inquiry and for an oral hearing - Misuse of powers)
(C/2026/648)
Language of the case: German

Parties


Applicant: LTV Leuchten & Lampen Vertriebs GmbH (Brunn am Gebirge, Austria) (represented by: C. Pilz, lawyer)

Defendant: European Union Intellectual Property Office (represented by: E. Markakis, acting as Agent)

Other party to the proceedings before the Board of Appeal of EUIPO, intervener before the General Court: XAL GmbH (Graz, Austria) (represented by: D. Jestaedt, lawyer)

Re:

By its action under Article 263 TFEU, the applicant seeks the alteration, or, at the very least, the annulment, of the decision of the Third Board of Appeal of the European Union Intellectual Property Office (EUIPO) of 9 December 2024 (Case R 2289/2023-3).

Operative part of the judgment

The Court:






1.


Dismisses the action;










2.


Orders LTV Leuchten & Lampen Vertriebs GmbH to bear its own costs and to pay those incurred by XAL GmbH;










3.


Orders the European Union Intellectual Property Office (EUIPO) to bear its own costs.






(1)  
            OJ C, C/2025/1663, 24.3.2025.


ELI: http://data.europa.eu/eli/C/2026/648/oj
ISSN 1977-091X (electronic edition)
Case T-848/25: Action brought on 10 December 2025 – Glock v EUIPO (Position of a rectangle on a pistol grip)
Date: 2025-12-10
Institutions: General Court
Subjects: EU trade mark, firearms and munitions, registered trade mark, small arms, toy industry, trade-mark law








C_202600670EN.000101.fmx.xml












Official Journal of the European Union


EN
C series













C/2026/670


9.2.2026






Action brought on 10 December 2025 – Glock v EUIPO (Position of a rectangle on a pistol grip)


(Case T-848/25)

(C/2026/670)
Language of the case: German

Parties


Applicant: Glock GmbH (Ferlach, Austria) (represented by: A. Koller, lawyer)

Defendant: European Union Intellectual Property Office (EUIPO)

Details of the proceedings before EUIPO


Trade mark at issue: Application for registration of the position mark for a rectangle on a pistol grip – Application No 19 117 092
         

Contested decision: Decision of the First Board of Appeal of EUIPO of 1 October 2025 in Case R 879/2025-1

Form of order sought

The applicant claims that the Court should:






—


annul or, where appropriate, alter the contested decision;










—


order EUIPO to pay to the designated legal representatives, within 14 days, the costs incurred by the applicant for the proceedings before the General Court and for the appeal proceedings, failing which enforcement action will be taken.





Plea in law







—


Infringement of Article 7(1)(b) of Regulation (EU) 2017/1001 of the European Parliament and of the Council.






ELI: http://data.europa.eu/eli/C/2026/670/oj
ISSN 1977-091X (electronic edition)
Case T-481/24: Judgment of the General Court of 10 December 2025 – Savencia v EUIPO – Hofmeister (Shape of a cheese) (EU trade mark – Opposition proceedings – International registration designating the European Union – Three-dimensional mark in the shape of a cheese – Earlier three-dimensional national marks – Relative ground for refusal – Likelihood of confusion – Global assessment of the likelihood of confusion – Distinctive character of the earlier mark – Article 8(1)(b) of Regulation (EU) 2017/1001)
Date: 2025-12-10
Institutions: General Court
Subjects: EU trade mark, animal fats, registered trade mark, trade-mark law, vegetable fats








C_202600643EN.000101.fmx.xml












Official Journal of the European Union


EN
C series













C/2026/643


9.2.2026






Judgment of the General Court of 10 December 2025 – Savencia v EUIPO – Hofmeister (Shape of a cheese)


(Case T-481/24)
                (1)

(EU trade mark - Opposition proceedings - International registration designating the European Union - Three-dimensional mark in the shape of a cheese - Earlier three-dimensional national marks - Relative ground for refusal - Likelihood of confusion - Global assessment of the likelihood of confusion - Distinctive character of the earlier mark - Article 8(1)(b) of Regulation (EU) 2017/1001)
(C/2026/643)
Language of the case: German

Parties


Applicant: Savencia SA (Viroflay, France) (represented by: G. Brox, F. Hagemann and A. Berger, lawyers)

Defendant: European Union Intellectual Property Office (represented by: T. Klee, acting as Agent)

Other party to the proceedings before the Board of Appeal of EUIPO, intervener before the General Court: Hofmeister Vermögensverwaltungs GmbH & Co. KG (Lauben, Germany) (represented by: F. Pfefferkorn, lawyer)

Re:

By its action under Article 263 TFEU, the applicant seeks the annulment of the decision of the Fifth Board of Appeal of the European Union Intellectual Property Office (EUIPO) of 8 July 2024 (Joined Cases R 1920/2022-5 and R 1941/2022-5).

Operative part of the judgment

The Court:






1.


Annuls the decision of the Fifth Board of Appeal of the European Union Intellectual Property Office (EUIPO) of 8 July 2024 (Joined Cases R 1920/2022-5 and R 1941/2022-5);










2.


Dismisses the action as to the remainder;










3.


Orders EUIPO to bear its own costs and pay those incurred by Savencia SA for the purposes of the proceedings before the General Court;










4.


Orders Hofmeister Vermögensverwaltungs GmbH & Co. KG to bear its own costs incurred in the proceedings before the General Court.






(1)  
            OJ C, C/2024/6447, 4. 11. 2024.


ELI: http://data.europa.eu/eli/C/2026/643/oj
ISSN 1977-091X (electronic edition)
Euro exchange rates – 9 December 2025
Date: 2025-12-10
Institutions: European Commission
Subjects: euro, exchange rate, money








C_202506387EN.000101.fmx.xml












Official Journal of the European Union


EN
C series













C/2025/6387


10.12.2025






Euro exchange rates (1)


            9 December 2025
         
(C/2025/6387)


1 euro =











 


Currency


Exchange rate




USD


US dollar


1,1637 




JPY


Japanese yen


181,96 




DKK


Danish krone


7,4689 




GBP


Pound sterling


0,87350 




SEK


Swedish krona


10,9015 




CHF


Swiss franc


0,9385 




ISK


Iceland króna


148,80 




NOK


Norwegian krone


11,7845 




BGN


Bulgarian lev


1,9558 




CZK


Czech koruna


24,277 




HUF


Hungarian forint


383,85 




PLN


Polish zloty


4,2303 




RON


Romanian leu


5,0897 




TRY


Turkish lira


49,5540 




AUD


Australian dollar


1,7532 




CAD


Canadian dollar


1,6114 




HKD


Hong Kong dollar


9,0560 




NZD


New Zealand dollar


2,0111 




SGD


Singapore dollar


1,5091 




KRW


South Korean won


1 708,91 




ZAR


South African rand


19,8661 




CNY


Chinese yuan renminbi


8,2207 




IDR


Indonesian rupiah


19 403,13 




MYR


Malaysian ringgit


4,7886 




PHP


Philippine peso


69,043 




RUB


Russian rouble


 




THB


Thai baht


37,070 




BRL


Brazilian real


6,3588 




MXN


Mexican peso


21,2691 




INR


Indian rupee


104,5500 






(1)  
            Source: reference exchange rate published by the ECB.


ELI: http://data.europa.eu/eli/C/2025/6387/oj
ISSN 1977-091X (electronic edition)
Notice for the attention of the persons subject to the restrictive measures provided for in Council Decision 2011/72/CFSP and Council Regulation (EU) No 101/2011 concerning restrictive measures directed against certain persons, entities and bodies in view of the situation in Tunisia
Date: 2025-12-10
Institutions: Council of the European Union
Subjects: EU restrictive measure, Tunisia, economic sanctions, international sanctions, natural person








C_202506693EN.000101.fmx.xml












Official Journal of the European Union


EN
C series













C/2025/6693


10.12.2025






Notice for the attention of the persons subject to the restrictive measures provided for in Council Decision 2011/72/CFSP and Council Regulation (EU) No 101/2011 concerning restrictive measures directed against certain persons, entities and bodies in view of the situation in Tunisia
(C/2025/6693)

The following information is brought to the attention of the persons that appear in the Annex to Council Decision 2011/72/CFSP (1), and in Annex I to Council Regulation (EU) No 101/2011 (2), concerning restrictive measures directed against certain persons, entities and bodies in view of the situation in Tunisia.
The Council has received information from the Tunisian authorities that will be considered within the framework of the annual review of the restrictive measures concerning all persons listed in the Annex to Decision 2011/72/CFSP and in Annex I to Regulation (EU) No 101/2011. The persons concerned are hereby informed that they may submit a request to the Council to obtain the information that relates to them, before 
            16 December 2025, to the following address:





Council of the European Union




General Secretariat




RELEX.1




Rue de la Loi/Wetstraat 175




1048 Bruxelles/Brussel




BELGIQUE/BELGIË




Email: sanctions@consilium.europa.eu





Any observations received will be taken into account for the purpose of the Council's periodic review, in accordance with Article 5 of Decision 2011/72/CFSP and Article 12(4) of Regulation (EU) No 101/2011.


(1)  
            OJ L 28, 2.2.2011, p. 62.

(2)  
            OJ L 31, 5.2.2011, p. 1.


ELI: http://data.europa.eu/eli/C/2025/6693/oj
ISSN 1977-091X (electronic edition)
Case T-844/25: Action brought on 10 December 2025 – Biohaven Bioscience Ireland and Biohaven Therapeutics v EMA
Date: 2025-12-10
Institutions: General Court
Subjects: confidentiality, drug surveillance, medicinal product, scientific report, trade information, withdrawal from the market








C_202600668EN.000101.fmx.xml












Official Journal of the European Union


EN
C series













C/2026/668


9.2.2026






Action brought on 10 December 2025 – Biohaven Bioscience Ireland and Biohaven Therapeutics v EMA


(Case T-844/25)

(C/2026/668)
Language of the case: English

Parties


Applicants: Biohaven Bioscience Ireland Ltd (Dublin, Ireland), Biohaven Therapeutics Ltd (Tortola, British Virgin Islands) (represented by: S. Drosos and K. Ewert, lawyers)

Defendant: European Medicines Agency

Form of order sought

The applicants claim that the Court should:






—


annul the decision of the EMA of 27 October 2025 to publish the Withdrawal European Public Assessment Report (‘WEPAR’) for the medicinal product Dazluma; and










—


order the European Medicines Agency to pay the applicants’ costs.





Pleas in law and main arguments

In support of the action, the applicants rely on three pleas in law.






1.


First plea in law, alleging an infringement of the duty to state reasons, as the EMA failed to explain why the entire WEPAR was not considered commercially confidential information.










2.


Second plea in law, alleging an incorrect application of Article 339 TFEU and Articles 11 and 76 of Regulation (EC) No 726/2004 (1), insofar as the EMA erroneously considered that the entire WEPAR for Dazluma did not temporarily qualify as commercially confidential information.










3.


Third plea in law, alleging an infringement of Article 339 TFEU and Articles 11 and 76 of Regulation (EC) No 726/2004, as the EMA failed to recognise that certain passages in the WEPAR constitute commercially confidential information.






(1)  Regulation (EC) No 726/2004 of the European Parliament and of the Council of 31 March 2004 laying down Union procedures for the authorisation and supervision of medicinal products for human use and establishing a European Medicines Agency (OJ 2004, L 136, p. 1).


ELI: http://data.europa.eu/eli/C/2026/668/oj
ISSN 1977-091X (electronic edition)